A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

Mark R. Litzow, Sandra Lee, John M. Bennett, Gordon W. Dewald, Robert E. Gallagher, Vibha Jain, Elisabeth M. Paietta, Janis Racevskis, Steven R. Rousey, Joseph J. Mazza, Martin S. Tallman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

Original languageEnglish (US)
Pages (from-to)1105-1108
Number of pages4
JournalHaematologica
Volume91
Issue number8
StatePublished - Aug 2006

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome
B-Lymphocytes
Therapeutics
Survival
Infection
arsenic trioxide

Keywords

  • Acute lymphoblastic leukemia
  • Arsenic trioxide
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Litzow, M. R., Lee, S., Bennett, J. M., Dewald, G. W., Gallagher, R. E., Jain, V., ... Tallman, M. S. (2006). A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica, 91(8), 1105-1108.

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. / Litzow, Mark R.; Lee, Sandra; Bennett, John M.; Dewald, Gordon W.; Gallagher, Robert E.; Jain, Vibha; Paietta, Elisabeth M.; Racevskis, Janis; Rousey, Steven R.; Mazza, Joseph J.; Tallman, Martin S.

In: Haematologica, Vol. 91, No. 8, 08.2006, p. 1105-1108.

Research output: Contribution to journalArticle

Litzow, MR, Lee, S, Bennett, JM, Dewald, GW, Gallagher, RE, Jain, V, Paietta, EM, Racevskis, J, Rousey, SR, Mazza, JJ & Tallman, MS 2006, 'A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia', Haematologica, vol. 91, no. 8, pp. 1105-1108.
Litzow MR, Lee S, Bennett JM, Dewald GW, Gallagher RE, Jain V et al. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica. 2006 Aug;91(8):1105-1108.
Litzow, Mark R. ; Lee, Sandra ; Bennett, John M. ; Dewald, Gordon W. ; Gallagher, Robert E. ; Jain, Vibha ; Paietta, Elisabeth M. ; Racevskis, Janis ; Rousey, Steven R. ; Mazza, Joseph J. ; Tallman, Martin S. / A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. In: Haematologica. 2006 ; Vol. 91, No. 8. pp. 1105-1108.
@article{6f00efbc5dce4074b7cdaecd21aa50c8,
title = "A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia",
abstract = "We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.",
keywords = "Acute lymphoblastic leukemia, Arsenic trioxide, Relapse",
author = "Litzow, {Mark R.} and Sandra Lee and Bennett, {John M.} and Dewald, {Gordon W.} and Gallagher, {Robert E.} and Vibha Jain and Paietta, {Elisabeth M.} and Janis Racevskis and Rousey, {Steven R.} and Mazza, {Joseph J.} and Tallman, {Martin S.}",
year = "2006",
month = "8",
language = "English (US)",
volume = "91",
pages = "1105--1108",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

TY - JOUR

T1 - A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

AU - Litzow, Mark R.

AU - Lee, Sandra

AU - Bennett, John M.

AU - Dewald, Gordon W.

AU - Gallagher, Robert E.

AU - Jain, Vibha

AU - Paietta, Elisabeth M.

AU - Racevskis, Janis

AU - Rousey, Steven R.

AU - Mazza, Joseph J.

AU - Tallman, Martin S.

PY - 2006/8

Y1 - 2006/8

N2 - We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

AB - We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

KW - Acute lymphoblastic leukemia

KW - Arsenic trioxide

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=33746979218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746979218&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 1105

EP - 1108

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -